checkAd

    Nordic Nanovector  231  0 Kommentare Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin in DLBCL - Seite 3

    This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

    This information was brought to you by Cision http://news.cision.com

    Lesen Sie auch

    https://news.cision.com/nordic-nanovector/r/nordic-nanovector--safety-review-committee-approves-advancing-to-final-dosing-regimen-in-phase-1-tri,c2785221


    PR Newswire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3
    Verfasst von PR Newswire (engl.)
    Nordic Nanovector Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin in DLBCL - Seite 3 OSLO, Norway, April 10, 2019 /PRNewswire/ - Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-05 clinical trial of single-administration Betalutin (177Lu-satetraxetan-lilotomab) in patients …